AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is a biopharmaceutical company specializing in the research and development of innovative immunology-based therapeutics. The company’s primary focus is on addressing unmet medical needs in oncology, immune disorders, and viral diseases, including high-profile conditions such as various cancers, chronic fatigue syndrome, and COVID-19. AIM ImmunoTech’s flagship product is Ampligen® (rintatolimod), a unique double-stranded RNA immunomodulator that functions as a selective TLR3 agonist. Ampligen is currently in multiple clinical trials targeting a broad range of solid tumors, immune system disorders, and viral infections, and is approved in Argentina for severe chronic fatigue syndrome. Another notable product, Alferon N Injection®, is approved in certain markets for treating specific viral infections such as refractory external genital warts. The company operates from Ocala, Florida, and collaborates with leading research centers and institutions worldwide. AIM ImmunoTech is recognized for its commitment to advancing immunotherapy solutions that harness and direct the body's own immune response, aiming to address some of the most challenging diseases in modern medicine.